Cite
HARVARD Citation
Sezer, O. et al. (2017). Effects of single‐agent bortezomib as post‐transplant consolidation therapy on multiple myeloma‐related bone disease: a randomized phase II study. British journal of haematology. pp. 61-71. [Online].